safety profile – Page 24 – Communicable Diseases Research

Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial

Clinical Trial

Published on 2021-04-012022-10-04
Journal: International journal of clinical practice [Category] SARS, 신약개발, 임상,

[키워드] absence approved arrhythmia assessment Azithromycin Baghdad biochemical parameter changes in Chi-square clinical effectiveness clinical symptom clinical trial conducted COVID-19 critical condition discharged Dizziness Effectiveness HCQ healthcare hospital hospitalisation Hydroxychloroquine hypoglycemia Intervention Iraq itching lab management measure medication Ministry of Health moderate Most patient natural trial outcome measure Pain paired t-test Patient patients patients died positive RT-PCR post-intervention promote Prospective Study QT prolongation reduced regimen reported RT-PCR Safety safety profile severity Side effect significantly skin rash study period Symptom symptoms of COVID-19 the disease therapy treat Treatment Treatment protocol Trial vital signs were used without symptom
[DOI] 10.1111/ijcp.13856 PMC 바로가기 [Article Type] Clinical Trial

Real-life use of remdesivir in hospitalized patients with COVID-19

COVID-19로 입원한 환자에서 렘데시비르의 실제 사용

Observational Study

Published on 2021-04-012022-09-11
Journal: Revista española de quimioterapia : publicación [Category] MERS, 임상, 진단, 치료제,

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study

COVID-19로 인한 호흡 부전 환자의 주요 임상 사건 예방 및 회복에 대한 다파글리플로진의 효과: DARE-19 연구의 설계 및 근거

Article

Published on 2021-04-012022-09-11
Journal: Diabetes, obesity & metabolism [Category] SARS, 임상,

[키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission Adult patients all-cause mortality atherosclerotic benefit cardiometabolic cardiometabolic risk factor cardiovascular cardiovascular disease caused Chronic kidney disease clinical recovery clinical status clinical trial composite endpoint coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 complications COVID-19-related complication COVID-19-related complications Critically ill Dapagliflozin diabetes double-blind Effect Efficacy Eligible patients Endpoint evaluate event Glucose heart failure Hierarchical high-risk patient High-risk patients Hospitalization hypothese IMPROVE incidence individuals with COVID-19 inhibitor International investigator-initiated kidney Kidney disease Kidney injury material morbidity and mortality multicentre multiorgan failure organ organ dysfunction Patient patient population patients hospitalized patients with COVID-19 phase III study Placebo placebo-controlled study Prevent Randomized Randomized controlled trial randomized trial reduce respiratory complication Respiratory complications Respiratory failure Safety safety profile SGLT2 inhibitor shown sodium Treatment type 2 diabete type 2 diabetes with COVID-19 worsened
[DOI] 10.1111/dom.14296 PMC 바로가기 [Article Type] Article

Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities

COVID-19에 대한 Ivermectin 용도 변경: 분자 측면 및 치료 가능성

Review

Published on 2021-03-302022-09-11
Journal: Frontiers in Immunology [Category] SARS, 신약개발, 진단, 치료법, 치료제,

Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report

중증 COVID-19 환자의 전신 진균 감염에 대한 토실리주맙의 역할: 증례 보고

Case Reports

Published on 2021-03-262022-09-12
Journal: Medicine [Category] SARS, 진단,

Adverse events associated with potential drugs for COVID-19: a case study from real-world data

COVID-19에 대한 잠재적인 약물과 관련된 부작용: 실제 데이터의 사례 연구

Article

Published on 2021-03-222022-09-11
Journal: Briefings in Bioinformatics [Category] SARS, 치료제,

Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance

Randomized Controlled Trial

Published on 2021-03-092022-10-05
Journal: Proceedings of the National Academy of Sciences of [Category] 임상,

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives

Molecular Biosciences

Published on 2021-03-082022-10-31
Journal: Frontiers in Molecular Biosciences [Category] COVID-19,

[키워드] antiviral drug antiviral drugs approach approval candidate caused clinical study clinical trial Clinical use combat component COVID-19 develop disease disrupting drug candidate effective vaccine Effectiveness Efficacy effort Epidemic evaluated Favipiravir FDA Future immunization implementation in vitro study Infectious disease nano-based approaches pandemic physicochemical property present rapid expansion Remdesivir required safety profile SARS-CoV-2 SARS-CoV-2 treatment status tested Therapeutic approach Therapeutics translation trials umifenovir unique Vaccine vaccine candidate Vaccines virus
[DOI] 10.3389/fmolb.2021.604447 PMC 바로가기 [Article Type] Molecular Biosciences

Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2

Original Article

Published on 2021-03-072022-10-31
Journal: Clinical & Translational Immunology [Category] COVID-19,

[키워드] ACE ACE‐2 ACE2 African antibody Antibody Response antigenic approach asked B‐cell binding blocked Blood Contact convalescent patient Convalescent patients COVID‐19 defined disease effective enzyme epitope exacerbate Identified identify immune response immunogens immunopathology induce Interaction memory B cells mice neutralising neutralising antibody objective overlapping peptide peptide epitopes peptides plasma Prevent Protein raised RBD receptor‐binding domain receptor‐binding domain reduced risk Region Result safety profile SARS‐CoV‐2 SARS‐CoV‐2‐specific antibody SARS‐CoV‐2 sera significantly South specificity Strains T‐cell responses tested tetramer staining the RBD the Spike the vaccine vaccinate Vaccine Vaccine development
[DOI] 10.1002/cti2.1260 PMC 바로가기 [Article Type] Original Article

Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates—A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics

Review

Published on 2021-03-052022-10-29
Journal: Microorganisms [Category] COVID-19,

[키워드] Antiviral broad-spectrum antiviral broad-spectrum antivirals candidate caused cellular complex Compound coronavirus COVID-19 CR-31-B drug eIF4A eukaryotic translation exhibiting fraction Future Helicase highlight host mRNA Impact increase in inhibitors inhibitory effect interactions Intervention limit maintaining mechanism of action mRNA outbreak pan-antiviral Pandemics protein synthesis Region Replication resulting RNA RNA secondary structure RNA virus RNA viruses rocaglates safety profile sequence Side effects silvestrol Strategy targeting therapeutic translation translation initiation unique Vaccine viral mRNA zoonotic origin Zotatifin
[DOI] 10.3390/microorganisms9030540 PMC 바로가기 [Article Type] Review